Publications by authors named "Carmelo Tibaldi"

Claim this Profile
B
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
Benedetta Pellegrino, Filippo Giovanardi, Carmelo Tibaldi, Luca Moscetti, Andrea Vingiani

Tumori· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Andrea Camerini, Francesca Mazzoni, Vieri Scotti, Carmelo Tibaldi, Andrea Sbrana

J Clin Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression.
Marzia Del Re, Giovanna Irene Luculli, Iacopo Petrini, Andrea Sbrana, Vieri Scotti, Carmelo Tibaldi

Transl Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
Carmelo Tibaldi, Francesca Mazzoni, Vieri Scotti, Enrico Vasile, Daniele Pozzessere

Anticancer Agents Med Chem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance.
Richard J Honeywell, Ietje Kathmann, Elisa Giovannetti, Carmelo Tibaldi, Egbert F Smit

Cancers (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A reply to "Immune related adverse events and response to immunotherapy: focus on corticosteroids.".
Editta Baldini, Carmelo Tibaldi

Lung Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Editta Baldini, Alice Lunghi, Enrico Cortesi, Daniele Turci, Diego Signorelli, Carmelo Tibaldi

Lung Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
Carmelo Tibaldi, Andrea Camerini, Marcello Tiseo, Francesca Mazzoni, Fausto Barbieri

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.
Francesca Toffalorio, Mariacarmela Santarpia, Davide Radice, Christopher Adrian Jaramillo, Gianluca Spitaleri, Carmelo Tibaldi

Oncotarget· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Carmelo Tibaldi, Alice Lunghi, Editta Baldini

World J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
Marcello Tiseo, Luca Boni, Francesca Ambrosio, Andrea Camerini, Editta Baldini, Carmelo Tibaldi

J Clin Oncol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview.
Carmelo Tibaldi, Armida D'Incecco, Alessandro Lagana

Anticancer Agents Med Chem· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Pierluigi Gasparini, Luciano Cascione, Lorenza Landi, Stefania Carasi, Francesca Lovat, Carmelo Tibaldi

Proc Natl Acad Sci U S A· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients.
Enrico Vasile, Carmelo Tibaldi, G Leticia Leon, Armida D'Incecco, Elisa Giovannetti

J Cancer Res Clin Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
Marcello Tiseo, Luca Boni, Francesca Ambrosio, Andrea Camerini, Maria Giuseppa Vitale, Carmelo Tibaldi

Clin Lung Cancer· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Lorenza Landi, Marcello Tiseo, Rita Chiari, Serena Ricciardi, Elisa Rossi, Carmelo Tibaldi

Clin Lung Cancer· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.
Virginia Rotella, Lorenzo Fornaro, Enrico Vasile, Carmelo Tibaldi, Laura Boldrini

J Exp Clin Cancer Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC--letter.
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A Zucali

Clin Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer.
Carmelo Tibaldi

Pharmacogenomics· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Andrea Ardizzoni, Marcello Tiseo, Luca Boni, Andrew D Vincent, Rodolfo Passalacqua, Carmelo Tibaldi

J Clin Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Marcello Tiseo, Elisa Giovannetti, Carmelo Tibaldi, Andrea Camerini, Francesco Di Costanzo

Lung Cancer· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
Ming Yin, Jingrong Yan, Alexandra Voutsina, Carmelo Tibaldi, David C Christiani

Lung Cancer· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.
Carmelo Tibaldi, Elisa Giovannetti, Enrico Vasile, Laura Boldrini, Marielle I Gallegos-Ruiz

J Thorac Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Clara Lemos, Elisa Giovannetti, Paolo A Zucali, Yehuda G Assaraf, George L Scheffer, Carmelo Tibaldi

Pharmacogenomics· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Sara Caponi, Enrico Vasile, Laura Ginocchi, Carmelo Tibaldi, Francesca Borghi

Clin Lung Cancer· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis